Nano-Porous Alumina Membranes for Enhanced Hemodialysis Performance

用于增强血液透析性能的纳米多孔氧化铝膜

基本信息

批准号：
7052580
负责人：
WILLIAM H VAN GEERTRUYDEN
金额：
$ 19.4万
依托单位：
EMV TECHNOLOGIES, LLC
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
起止时间：
2006-09-20 至 2007-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7052580
关键词：
aluminum oxide artificial membranes bioengineering /biomedical engineering biomaterial development /preparation chronic renal failure hemodialysis membrane permeability molecular weight polymers scanning electron microscopy serum albumin technology /technique development thermostability

项目摘要

DESCRIPTION (provided by applicant): End stage renal disease (ESRD) has consistently been a major medical problem worldwide. By the year 2010, the number of ESRD patients in the United States is projected to be 661,330 with an increase of 78% compared to 372,407 in the year 2000. The total annual cost of Medicare for ESRD patients in the United States is projected to be $28.3 billion by the year 2010, an increase of 99% compared to $14.2 billion in the year 2000. Current hemodialysis membranes used in kidney dialysis have difficulty in removing uremic toxins from the blood. Nano-porous alumina tubes have gained significant interest in drug delivery and gas separation technologies and, as of yet, their use as membranes for hemodialysis has not been researched. The objective of this project is to create nano-porous alumina tubes with average pore sizes of 5 nm using a process of anodizing aluminum tubes under controlled conditions. There are several advantages of alumina membranes over the membranes currently used including: high porosity and uniform pore size, high hydraulic conductivity (water permeability), uniform pore distribution, excellent pore structure, high resistance to chemical and thermal degradation, and superior mechanical properties. The pore size and porosity will be measured by Scanning Electron Microscopy (SEM), while membrane permeability will be tested by a custom designed setup. Finally, a prototype mini-module hemodialyzer will be constructed and the clearance of a wide spectrum of molecular weight solutes (from low to high molecular weight solutes) will be evaluated. This research will address the needs of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), specifically its Division of Kidney, Urologic, and Hematologic Diseases. The NIDDK is seeking "the development of new dialysis membranes to diminish the duration of dialysis treatments." When commercialized, the new membranes will deliver a higher average dose to dialysis patients and increase their quality of life.

描述（由申请人提供）：末期肾脏疾病（ESRD）一直是全球主要的医学问题。到2010年，美国的ESRD患者人数预计为661,330，增加了78％，而2000年为372,407。ESRD患者的Medicare年度总成本预计在2010年为283亿美元，在2010年增加了283亿美元，在99％的票据中，与当前的HEAM INMED相比，该年度为14.2美元。透析难以从血液中去除尿毒症毒素。纳米型氧化铝管已经对药物输送和气体分离技术产生了重大兴趣，并且尚未研究它们作为血液透析膜的使用。该项目的目的是使用在受控条件下阳极氧化铝管的过程创建纳米孔氧化铝管，平均孔径为5 nm。与当前使用的膜相比，氧化铝膜有几个优点，包括：高孔隙率和均匀的孔径，高液压电导率（水渗透率），均匀的孔分布，出色的孔结构，对化学和热降解的高电阻，以及卓越的机械性能。孔径和孔隙率将通过扫描电子显微镜（SEM）来测量，而膜渗透性将通过自定义设计的设置进行测试。最后，将构建一个原型迷你模块血液赖兰，并将评估各种分子量溶质（从低分子量溶质到高分子量溶质）的清除。这项研究将满足国家糖尿病与消化研究所和肾脏疾病（NIDDK）的需求，特别是其肾脏，泌尿科和血液学疾病的分裂。 NIDDK正在寻求“开发新的透析膜，以减少透析治疗的持续时间”。商业化后，新膜将为透析患者提供更高的平均剂量并提高其生活质量。